Continuous glucose monitors (CGMs) give non-diabetics real-time metabolic feedback that fasting glucose and HbA1c can't provide. Here's which device is right for your longevity protocol in 2026.
Glucose dysregulation is one of the most prevalent and consequential metabolic problems in modern adults — and one of the most invisible. Fasting glucose tests measure a single snapshot. HbA1c reflects a 90-day average. Neither captures what happens to your glucose in the two hours after a meal, how high you spike on a low-glycemic-index food that happens to interact poorly with your individual microbiome, or whether your glucose is crashing at 3am. Continuous glucose monitors (CGMs) fill this gap: a wearable sensor applied to the upper arm provides real-time glucose readings every 1–5 minutes, 24 hours a day, for 14 days per sensor.
Dr. Peter Attia has been one of the most vocal advocates for CGM use in metabolically healthy non-diabetics, arguing that the data CGMs provide — particularly postprandial glucose excursions, time-in-range, and nocturnal stability — reveals patterns that are both individually variable and clinically actionable. "I put a CGM on virtually every patient," Attia has stated. "The data it provides about individual glucose responses is invaluable for metabolic optimization." Dr. Andrew Huberman has similarly discussed CGM use as one of the most powerful available biofeedback tools, noting that seeing your real-time glucose response to food fundamentally changes behavior. Glucose Revolution author Jessie Inchauspe built her entire framework — and bestselling book — on insights derived from her own CGM data.
Postprandial glucose spikes — even those that return to baseline within two hours — are increasingly recognized as independent cardiovascular and metabolic risk factors. Research published in the European Heart Journal demonstrated that non-diabetic individuals whose glucose exceeded 140 mg/dL after meals (a level below the diabetic threshold) had measurably higher levels of oxidative stress markers and endothelial dysfunction than those with flatter responses. The NutriNet-Santé study of 100,000 people found that glucose variability, not just average glucose, was associated with cardiovascular events.
For longevity-focused individuals, CGM data answers questions that no other accessible test can: Which specific foods spike your glucose beyond 140 mg/dL? Does exercise timing affect postprandial responses? Is your fasting glucose actually stable overnight, or are you experiencing nocturnal hypoglycemia? How does alcohol affect your glucose pattern? How does sleep deprivation alter glucose tolerance the next day? These are mechanistically important questions, and CGMs are the only practical way to answer them with personalized data.
Until 2024, continuous glucose monitors required a physician prescription in the United States. The regulatory landscape changed with FDA clearance of over-the-counter CGMs — first Dexcom Stelo, then Abbott Lingo — making CGM data accessible to the 25% of American adults in prediabetes and the larger group of metabolically healthy people who want real-time metabolic feedback. This has made CGM one of the fastest-growing segments of the consumer health market.
The Dexcom Stelo was the first FDA-cleared OTC CGM and remains the category benchmark. It uses Dexcom's established enzymatic glucose sensing technology, worn on the upper arm, replacing every 15 days (the longest wear period of any OTC CGM). Accuracy is excellent — MARD (mean absolute relative difference) of approximately 7.8%, comparable to Dexcom's prescription devices. The companion app provides real-time glucose graphs, trend arrows, and meal-logging integration. Stelo is designed specifically for non-diabetics: the alert thresholds are calibrated for the healthy range, and the app's AI-generated insights focus on dietary and lifestyle patterns rather than medical management.
Abbott's Lingo CGM uses the FreeStyle Libre sensing platform (the world's most widely used CGM) in a new consumer-focused form factor designed for non-diabetics. The 14-day sensor is applied to the upper arm and reads via NFC tap (like FreeStyle Libre) or continuous Bluetooth streaming (unlike the original Libre). Abbott's Lingo app focuses heavily on metabolic coaching: it scores your glucose responses to meals on a "bioscore" system, provides food-specific insights, and recommends behavioral adjustments based on your patterns. For users who want a guided experience rather than raw data, Lingo's coaching layer is the strongest in the OTC CGM category.
For users who have insurance coverage or can obtain a prescription (from a physician open to off-label use in non-diabetics), the FreeStyle Libre 3 remains an excellent choice. The Libre 3 delivers continuous Bluetooth streaming with automatic 1-minute updates — no scanning required — and is the thinnest CGM sensor currently available. MARD accuracy is approximately 7.7%, essentially equivalent to Dexcom Stelo. If your physician or functional medicine doctor will prescribe it, Libre 3 with insurance coverage is significantly more cost-effective than the OTC options.
While no wearable ring can directly measure glucose, the Oura Ring Gen 4's heart rate variability (HRV) and resting heart rate data serves as a useful complement to CGM data: acute glucose spikes typically elevate heart rate and suppress HRV, providing a secondary physiological signal that correlates with metabolic stress. For users who have completed a CGM learning period and understand their personal glucose patterns, Oura data can help identify which dietary or lifestyle situations are producing the most metabolic disruption — even without an active sensor.
The most common mistake first-time CGM users make is treating every glucose spike as a crisis. Normal postprandial glucose rises to 110–140 mg/dL are physiologically normal and do not indicate metabolic dysfunction — the relevant metric is how quickly glucose returns to baseline (within 2 hours) and whether you frequently exceed 140 mg/dL. The CGM insights that actually drive behavioral change are: identifying specific high-spike foods that you expected to be benign (many people discover rice, oats, or bananas spike them more than expected); discovering that exercise timing — particularly a 10-minute walk after eating — dramatically reduces postprandial peaks; and learning whether evening alcohol consumption destabilizes overnight glucose.
Peter Attia's recommended protocol for non-diabetic CGM use: three to four 14-day wear cycles per year during dedicated learning periods, focusing each cycle on a specific question (dietary patterns, exercise timing, stress effects, alcohol impact) rather than wearing continuously in an unfocused way. This approach generates specific actionable insights without the ongoing cost and data-saturation of continuous wear.
A home HbA1c test kit used every 90 days provides a longer-term metabolic marker to pair with your CGM data, giving you both the granular real-time picture and the 90-day trend.
The combination of periodic CGM use, regular HbA1c testing, and data-driven dietary adjustments represents one of the most actionable metabolic optimization protocols available to non-diabetics in 2026 — a direct application of the quantified self approach to one of the most consequential risk factors for cardiovascular disease, dementia, and metabolic aging.
Not everyone needs a CGM. The highest-yield candidates are: adults with fasting glucose above 90 mg/dL (a range associated with measurably higher cardiovascular risk even before the prediabetes threshold of 100 mg/dL); anyone with a first-degree relative with type 2 diabetes; adults over 50 with elevated triglycerides or visceral adiposity; and anyone who has gained significant weight in the past decade. For metabolically optimal adults under 40 with no risk factors, a single 14-day CGM cycle every one to two years is sufficient to confirm that metabolic health is genuinely good — and to catch any changes before they become entrenched. The democratization of CGM access through OTC devices in 2024–2026 makes this kind of metabolic self-assessment accessible in a way that was not possible even three years ago.